BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36724689)

  • 1. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
    Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
    Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG.
    Nikolaev A; Fiveash JB; Yang ES
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
    Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
    Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
    Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential.
    Kfoury-Beaumont N; Prakasam R; Pondugula S; Lagas JS; Matkovich S; Gontarz P; Yang L; Yano H; Kim AH; Rubin JB; Kroll KL
    BMC Biol; 2022 May; 20(1):124. PubMed ID: 35637482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
    Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
    Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
    Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
    Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
    Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
    Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
    van den Bent M; Saratsis AM; Geurts M; Franceschi E
    Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
    Lu VM; Daniels DJ
    Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.